Abstract
Due to lack of effective therapy, primary brain tumors are the focus of intense investigation of novel experimental approaches that use vectors and recombinant viruses. Therapeutic approaches have been both indirect, whereby vectors are used, or direct to allow for direct cell killing by the introduced virus. Genetically engineered herpes simplex viruses are currently being evaluated as an experimental approach to eradicate malignant human gliomas. Initial studies with γ134.5 mutants, R3616 (from which both copies of the γ134.5 gene have been deleted) and R4009 (a construct with two stop codons inserted into the γ134.5 gene), have been assessed. In a syngeneic scid mouse intracranial tumor model, recombinant herpes simplex virus can be experimentally used for the treatment of brain tumors. These viruses and additional engineered viruses were subsequently tested in human glioma cells both in vitro and in vivo. Using a xenogeneic scid mouse intracranial glioma model, R4009 therapy of established tumors significantly prolonged survival. Most importantly, long-term survival was achieved, with histologic evidence that R4009 eradicated intracranial tumors in this model. Furthermore, the opportunity to evaluate γ134.5 mutants that have enhanced oncolytic activity, e.g., R8309 where the carboxyl terminus of the γ134.5 gene has been replaced by the murine homologue, MyD116, are considered.
| Original language | English |
|---|---|
| Pages (from-to) | 11313-11318 |
| Number of pages | 6 |
| Journal | Proceedings of the National Academy of Sciences of the United States of America |
| Volume | 93 |
| Issue number | 21 |
| DOIs | |
| State | Published - Oct 15 1996 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Genetics
- General
Cite this
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. / Andreansky, Samita; He, Bin; Gillespie, G. Yancey; Soroceanu, Liliana; Markert, James; Chou, Joany; Roizman, Bernard; Whitley, Richard J.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, No. 21, 15.10.1996, p. 11313-11318.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
AU - Andreansky, Samita
AU - He, Bin
AU - Gillespie, G. Yancey
AU - Soroceanu, Liliana
AU - Markert, James
AU - Chou, Joany
AU - Roizman, Bernard
AU - Whitley, Richard J.
PY - 1996/10/15
Y1 - 1996/10/15
N2 - Due to lack of effective therapy, primary brain tumors are the focus of intense investigation of novel experimental approaches that use vectors and recombinant viruses. Therapeutic approaches have been both indirect, whereby vectors are used, or direct to allow for direct cell killing by the introduced virus. Genetically engineered herpes simplex viruses are currently being evaluated as an experimental approach to eradicate malignant human gliomas. Initial studies with γ134.5 mutants, R3616 (from which both copies of the γ134.5 gene have been deleted) and R4009 (a construct with two stop codons inserted into the γ134.5 gene), have been assessed. In a syngeneic scid mouse intracranial tumor model, recombinant herpes simplex virus can be experimentally used for the treatment of brain tumors. These viruses and additional engineered viruses were subsequently tested in human glioma cells both in vitro and in vivo. Using a xenogeneic scid mouse intracranial glioma model, R4009 therapy of established tumors significantly prolonged survival. Most importantly, long-term survival was achieved, with histologic evidence that R4009 eradicated intracranial tumors in this model. Furthermore, the opportunity to evaluate γ134.5 mutants that have enhanced oncolytic activity, e.g., R8309 where the carboxyl terminus of the γ134.5 gene has been replaced by the murine homologue, MyD116, are considered.
AB - Due to lack of effective therapy, primary brain tumors are the focus of intense investigation of novel experimental approaches that use vectors and recombinant viruses. Therapeutic approaches have been both indirect, whereby vectors are used, or direct to allow for direct cell killing by the introduced virus. Genetically engineered herpes simplex viruses are currently being evaluated as an experimental approach to eradicate malignant human gliomas. Initial studies with γ134.5 mutants, R3616 (from which both copies of the γ134.5 gene have been deleted) and R4009 (a construct with two stop codons inserted into the γ134.5 gene), have been assessed. In a syngeneic scid mouse intracranial tumor model, recombinant herpes simplex virus can be experimentally used for the treatment of brain tumors. These viruses and additional engineered viruses were subsequently tested in human glioma cells both in vitro and in vivo. Using a xenogeneic scid mouse intracranial glioma model, R4009 therapy of established tumors significantly prolonged survival. Most importantly, long-term survival was achieved, with histologic evidence that R4009 eradicated intracranial tumors in this model. Furthermore, the opportunity to evaluate γ134.5 mutants that have enhanced oncolytic activity, e.g., R8309 where the carboxyl terminus of the γ134.5 gene has been replaced by the murine homologue, MyD116, are considered.
UR - http://www.scopus.com/inward/record.url?scp=0029961357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029961357&partnerID=8YFLogxK
U2 - 10.1073/pnas.93.21.11313
DO - 10.1073/pnas.93.21.11313
M3 - Article
VL - 93
SP - 11313
EP - 11318
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
SN - 0027-8424
IS - 21
ER -